Roth Capital reaffirmed their buy rating on shares of Matinas BioPharma Holdings Inc (NYSEMKT:MTNB) in a research note published on Monday, July 10th.

Shares of Matinas BioPharma Holdings (NYSEMKT MTNB) traded up 3.57% during midday trading on Monday, reaching $1.16. 376,468 shares of the company’s stock were exchanged. Matinas BioPharma Holdings has a 12 month low of $0.63 and a 12 month high of $3.99. The company’s 50 day moving average is $1.79 and its 200-day moving average is $2.59. The stock’s market cap is $106.02 million.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at

Matinas BioPharma Holdings Company Profile

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Stock Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related stocks with our FREE daily email newsletter.